INHIBRX BIOSCIENCES, INC. Operating Cash Flow
INHIBRX BIOSCIENCES, INC. (INBX) reported Operating Cash Flow of -$67.94 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Cash Flow › Operating Activities
us-gaap:NetCashProvidedByUsedInOperatingActivities · last filed 2026-08-13
- INHIBRX BIOSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2026-06-30 was -$29.92M.
- INHIBRX BIOSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2026-03-31 was -$38.03M.
- INHIBRX BIOSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2025-12-31 was -$30.12M.
- INHIBRX BIOSCIENCES, INC. net cash provided by (used in) operating activities for the quarter ending 2025-09-30 was -$33.82M.
- INHIBRX BIOSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2025 was -$129.79M.
- INHIBRX BIOSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2024 was -$194.41M.
- INHIBRX BIOSCIENCES, INC. net cash provided by (used in) operating activities for fiscal 2023 was -$193.31M.
| Period end | Net Cash Provided by (Used in) Operating Activities 3 month | Net Cash Provided by (Used in) Operating Activities 6 month | Net Cash Provided by (Used in) Operating Activities 9 month | Net Cash Provided by (Used in) Operating Activities 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$29.92M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$67.94M 10-Q · filed 2026-08-13 | -$98.06M derived: sum of 3 quarters · filed 2026-08-13 | -$131.89M derived: sum of 4 quarters · filed 2026-08-13 |
| 2026-03-31 | -$38.03M 10-Q · filed 2026-05-14 | -$68.15M derived: sum of 2 quarters · filed 2026-05-14 | -$101.97M derived: sum of 3 quarters · filed 2026-05-14 | -$131.93M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-12-31 | -$30.12M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$63.95M derived: sum of 2 quarters · filed 2026-03-19 | -$93.90M derived: sum of 3 quarters · filed 2026-08-13 | -$129.79M 10-K · filed 2026-03-19 |
| 2025-09-30 | -$33.82M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$63.78M derived: sum of 2 quarters · filed 2026-08-13 | -$99.67M 10-Q · filed 2025-11-14 | -$143.39M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-06-30 | -$29.95M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-13 | -$65.85M 10-Q · filed 2026-08-13 | -$109.57M derived: sum of 3 quarters · filed 2026-08-13 | -$139.85M derived: sum of 4 quarters · filed 2026-08-13 |
| 2025-03-31 | -$35.90M 10-Q · filed 2026-05-14 | -$79.61M derived: sum of 2 quarters · filed 2026-05-14 | -$109.90M derived: sum of 3 quarters · filed 2026-05-14 | -$167.25M derived: sum of 4 quarters · filed 2026-05-14 |
| 2024-12-31 | -$43.72M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-19 | -$74.00M derived: sum of 2 quarters · filed 2026-03-19 | -$131.36M derived: sum of 3 quarters · filed 2026-03-19 | -$194.41M 10-K · filed 2026-03-19 |
| 2024-09-30 | -$30.28M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | -$87.64M derived: sum of 2 quarters · filed 2025-11-14 | -$150.69M 10-Q · filed 2025-11-14 | -$207.51M derived: sum of 4 quarters · filed 2025-11-14 |
| 2024-06-30 | -$57.36M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | -$120.41M 10-Q · filed 2025-08-13 | -$177.23M derived: sum of 3 quarters · filed 2025-08-13 | -$231.47M derived: sum of 4 quarters · filed 2025-08-13 |
| 2024-03-31 | -$63.05M 10-Q · filed 2025-05-14 | -$119.87M derived: sum of 2 quarters · filed 2025-05-14 | -$174.12M derived: sum of 3 quarters · filed 2025-05-14 | |
| 2023-12-31 | -$56.82M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-17 | -$111.07M derived: sum of 2 quarters · filed 2025-03-17 | -$193.31M 10-K · filed 2025-03-17 | |
| 2023-09-30 | -$54.24M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | -$136.49M 10-Q · filed 2024-11-14 | ||
| 2023-06-30 | -$82.24M 10-Q · filed 2024-08-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Maze Therapeutics, Inc. (MAZE) | United States | $1.457B | -12.40 |
| Taysha Gene Therapies, Inc. (TSHA) | United States | $1.564B | -14.80 |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 | |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |